Written Question·Department of Health and Social Care·UIN HL1762

Breast Cancer: Drugs

Tabled: 7 July 2026

Answered: 16 July 2026

Question

To ask His Majesty's Government what estimate they have made of the impact of the lack of accessibility of the Enhertu drug for HER2-low metastatic breast cancer in England upon the objective of becoming one of the top three fastest places in Europe for p

Answer

HER2‑low breast cancer is managed with treatments for HER2‑negative breast cancer. The National Institute for Health and Care Excellence (NICE) has published guidance recommending a number of medicines for the treatment of HER2-negative breast cancer whic...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN HL1762) →